Duke spinout Istari Oncology has collected $43.5m out of a targeted $70m for its latest round.
Istari Oncology, a US-based biotechnology spinout of Duke University, has secured $43.5m out of a targeted $70m, according to a regulatory filing.
Founded in 2015, Istari Oncology is working on a therapy for bladder cancer that uses a modified poliovirus. The spinout had its application for an investigational new drug approved by the Food and Drug Administration yesterday.
The spinout is also running ongoing trials for immunotherapies aimed at recurrent glioblastoma and refractory melanoma.
Istari secured $1.1m…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
